Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-741672 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-741672 | DRUG | Tablets, Oral, 100 mg, once daily, 3 weeks |
| Placebo | DRUG | Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up |
Inclusion Criteria: * Type 1 or 2 diabetics with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least 12 months duration * Screening HbA1c of ≥ 7% and ≤ 10% * BMI ≤ 40 kg/m2 Exclusion Criteria: * Patients with clinically significant, progressive, or potential...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
| Boston Scientific Corporation | BSX | 1 | N/A | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | N/A | Undisclosed |
BMS-741672 is an investigational small molecule being developed for the treatment of neuropathic pain, specifically diabetic neuropathic pain. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
BMS-741672 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
BMS-741672 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 2 trial has been completed.
BMS-741672 has one completed clinical trial, NCT00683423, titled 'BMS-741672 for Diabetic Neuropathic Pain.' This Phase 2 study enrolled 50 participants in the United States and was placebo-controlled, randomized, and double-blind.
No, BMS-741672 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for neuropathic pain. Its safety and efficacy have not been established, and it remains under clinical investigation.